Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidanc...(cluding PLICERA SPD550AMIGAL JUVISTA and...)

% of % of

product product

2008 sales 2007 sales

$m $m

_________ _________ _________ _________

SG&A (US GAAP) 428.8 61% 280.6 56%

Costs associated with the

introduction of a new

holding company

(6.6) -

Amortization (31.0) (17.6)

Impairment of intangible (90.4) -

assets

Depreciation (11.2) (9.9)

_________ _________

SG&A (Non GAAP) 289.6 41% 253.1 50%

_________ _________

SG&A expenses increased to $428.8 million for the three months to June 30, 2008 from $280.6 million in the corresponding period in 2007. Excluding an intangible asset impairment charge of $90.4 million in respect of DYNEPO, amortization of intangible assets (increased due to VYVANSE, launched July 2007), costs associated with the introduction of the new holding company and depreciation costs (see reconciliation table above), SG&A expenditure increased by $36.5 million to $289.6 million.

Excluding these items, SG&A decreased as a percentage of product sales to 41% (2007: 50%) reflecting the sales impact in the three months to June 30, 2008 of the successful launches of VYVANSE, LIALDA/MEZAVANT and ELAPRASE.

Other increases in SG&A expens
'/>"/>